



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Ilicicolin A

Cat. No.:	HY-122108
CAS No.:	22581-06-2
Molecular Formula:	C ₂₃ H ₃₁ ClO ₃
Molecular Weight:	390.94
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ilicicolin A is a potent anticancer agent. Ilicicolin A induces apoptosis. Ilicicolin A inhibits cell growth and colony formation. Ilicicolin A shows antitumor activity. Ilicicolin A has the potential for the research of prostate cancer ^[1] .																				
In Vitro	<p>Ilicicolin A (0, 2.5, 5, 10 μM; 48 h) induces apoptosis in 22Rv1, C4-2B cells^[1].</p> <p>Ilicicolin A (0, 2.5, 5, 10 μM) inhibits cell growth and colony formation in 22Rv1 cells and C4-2B cells in a dose-dependent manner^[1].</p> <p>Ilicicolin A (0, 2.5, 5, 10 μM; 48 h) decreases the protein expression of EZH2, AURKA, PLK1, FoxM1, Cyclin B2, AR, c-Myc, cyclin D1^[1].</p> <p>Ilicicolin A (0, 2.5, 5, 10 μM; 48 h) decreases the mRNA expression of AR, ALK2, ALK3 in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>22Rv1, C4-2B cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 2.5, 5, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>96 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell growth in a dose-dependent manner.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>22Rv1, C4-2B cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 2.5, 5, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis and increased the expression of cleaved-PARP1 and cleaved caspase 7.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>22Rv1, C4-2B cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 2.5, 5, 10 μM</td> </tr> </table>	Cell Line:	22Rv1, C4-2B cells	Concentration:	0, 2.5, 5, 10 μM	Incubation Time:	96 h	Result:	Inhibited cell growth in a dose-dependent manner.	Cell Line:	22Rv1, C4-2B cells	Concentration:	0, 2.5, 5, 10 μM	Incubation Time:	48 h	Result:	Induced apoptosis and increased the expression of cleaved-PARP1 and cleaved caspase 7.	Cell Line:	22Rv1, C4-2B cells	Concentration:	0, 2.5, 5, 10 μM
Cell Line:	22Rv1, C4-2B cells																				
Concentration:	0, 2.5, 5, 10 μM																				
Incubation Time:	96 h																				
Result:	Inhibited cell growth in a dose-dependent manner.																				
Cell Line:	22Rv1, C4-2B cells																				
Concentration:	0, 2.5, 5, 10 μM																				
Incubation Time:	48 h																				
Result:	Induced apoptosis and increased the expression of cleaved-PARP1 and cleaved caspase 7.																				
Cell Line:	22Rv1, C4-2B cells																				
Concentration:	0, 2.5, 5, 10 μM																				

	<table border="1"> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the expression of EZH2, AURKA, PLK1, FoxM1, Cyclin B2, AR, c-Myc, cyclin D1.</td> </tr> <tr> <td colspan="2">RT-PCR^[1]</td> </tr> <tr> <td>Cell Line:</td> <td>22Rv1, C4-2B cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 2.5, 5, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the mRNA expression of AR, ALK2, ALK3 in a dose-dependent manner.</td> </tr> </table>	Incubation Time:	48 h	Result:	Decreased the expression of EZH2, AURKA, PLK1, FoxM1, Cyclin B2, AR, c-Myc, cyclin D1.	RT-PCR ^[1]		Cell Line:	22Rv1, C4-2B cells	Concentration:	0, 2.5, 5, 10 μ M	Incubation Time:	48 h	Result:	Decreased the mRNA expression of AR, ALK2, ALK3 in a dose-dependent manner.
Incubation Time:	48 h														
Result:	Decreased the expression of EZH2, AURKA, PLK1, FoxM1, Cyclin B2, AR, c-Myc, cyclin D1.														
RT-PCR ^[1]															
Cell Line:	22Rv1, C4-2B cells														
Concentration:	0, 2.5, 5, 10 μ M														
Incubation Time:	48 h														
Result:	Decreased the mRNA expression of AR, ALK2, ALK3 in a dose-dependent manner.														
In Vivo	<p>Illicicolin A (10 mg/kg; i.p.; six times a week for 3 weeks) inhibits tumor growth in mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Four-week-old, 18 g, male NOD/SCID mice (22Rv1 cells) ^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; six times a week for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Suppressed tumor growth but did not elicit a significant effect on bodyweight.</td> </tr> </table>	Animal Model:	Four-week-old, 18 g, male NOD/SCID mice (22Rv1 cells) ^[1]	Dosage:	10 mg/kg	Administration:	i.p.; six times a week for 3 weeks	Result:	Suppressed tumor growth but did not elicit a significant effect on bodyweight.						
Animal Model:	Four-week-old, 18 g, male NOD/SCID mice (22Rv1 cells) ^[1]														
Dosage:	10 mg/kg														
Administration:	i.p.; six times a week for 3 weeks														
Result:	Suppressed tumor growth but did not elicit a significant effect on bodyweight.														

REFERENCES

[1]. Guo L, et al. Illicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway. Front Pharmacol. 2021 Oct 27;12:723729.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA